IFNB1 and myeloid sarcoma: At present, the products approved by the FDA for the treatment of MS include interferon (IFN)-β, glatiramer acetate (GA), teriflunomide, fingolimod (FTY), mitoxantrone, natalizumab, dimethyl fumarate, and alemtuzumab (Table 1).